Development of treatment
for patients

Other Therapy

MU-D201

Innovative agent inhibits TGF-β signaling
and epigenetic mechanisms in cancer

First Discovery of DRAK2 Target Protein

- When DRAK2 is overexpressed in cancer tissues, it inhibits the inhibitory activity of TGF-β to promote cancer growth and metastasis

Drug Development Roadmap

  • Small Molecule Compound

    MU-D201

  • Biomarker

    EZH2 gene mutation, gamma delta (γδ) T-cell receptor mutation

Fast track commercial approval expected for treatment of rare diseases

  • (Diffuse large B-cell lymphoma which is characterized by EZH2 gene mutations and gamma delta (γδ) T-cell leukemia)

Diffuse large B-cell lymphoma

DRAK2 is overexpressed in diffuse giant B cell lymphoma cells with EZH2 gene mutation.

Gamma delta (γδ) T-cell leukemia

DRAK2 inhibitor MU-D201 induces apoptosis in gamma delta T cell lymphoid leukemia cells